Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
Mohamad Khatib, Karimulla S. Shaik, Amna Ahmed, Mohammad Alwraidat, Ahmed S. Mohamed, Mohamad R. Abou Kamar, Mouhammad Z. Sharaf Eldean, Bashar K. Aldaraiseh, Abdulqadir J. Nashwan
Abstract
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.
Topics & Concepts
MedicineTocilizumabCoronavirus disease 2019 (COVID-19)CytomegalovirusPerforationColitisBowel perforationCytomegalovirus infectionsGastroenterologyInternal medicine2019-20 coronavirus outbreakIntensive care medicineSurgeryImmunologyVirologyComplicationHuman immunodeficiency virus (HIV)VirusViral diseaseHuman cytomegalovirusHerpesviridaeOutbreakPunchingMetallurgyInfectious disease (medical specialty)Materials scienceDiseaseCytomegalovirus and herpesvirus researchImmunodeficiency and Autoimmune DisordersPneumocystis jirovecii pneumonia detection and treatment